The updated NCCN Guidelines for Non-Small Cell Lung Cancer now include a description of maintenance therapy for patients with advanced or metastatic disease. This new section helps distinguish between recommended therapies for continuation maintenance versus switch maintenance.
Erlotinib has been added as a first-line treatment option for EGFR mutation positive patients with advanced or metastatic disease with a category 2A designation. Bevacizumab and cetuximab have been added as treatment options for continuation maintenance with a category 1 designation. Pemetrexed and erlotinib have been added as treatment options for switch maintenance with a category 2B designation and docetaxel has been added as a treatment option for switch maintenance with a category 3 designation.